ARTICLE | Clinical News

GlycoMimetics reports updated Phase I/II AML data for GMI-1271

December 15, 2017 5:02 PM UTC

GlycoMimetics (NASDAQ:GLYC) reported updated data at the American Society of Hematology meeting from a Phase I/II trial of GMI-1271 to treat acute myelogenous leukemia (AML). The company plans to start a Phase III trial in mid-2018 of the E selectin (SELE; CD62E) antagonist.

In 54 relapsed or refractory AML patients with a median follow-up of 6.6 months, 10 mg/kg GMI-1271 plus mitoxantrone, etoposide and cytarabine (MEC) chemotherapy led to a median overall survival (OS) of 9.4 months, which GlycoMimetics said "compares favorably" to a median OS of up to 5.4 months for historical controls treated with MEC alone. GMI-1271 plus MEC led to a rate of complete remission (CR) or CR with incomplete blood count recovery (CRi) of 43%, with a median duration of remission of 11.1 months...